title: Microbiological characteristics of acute prostatitis after transrectal prostate biopsy.
abstract: OBJECTIVE
  We aimed to identify microbiological characteristics in patients with acute prostatitis after transrectal prostate biopsy to provide guidance in the review of prevention and treatment protocols.
  
  
  METHODS
  A retrospective analysis of medical records was performed in 1,814 cases who underwent prostate biopsy at Seoul St. Mary's Hospital and St. Vincent's Hospital over a 5 year period from 2006 to 2011. Cases in which acute prostatitis occurred within 7 days after the biopsy were investigated. Before starting treatment with antibiotics, sample collections were done for culture of urine and blood. Culture and drug susceptibility was identified by use of a method established by the Clinical and Laboratory Standards Institute.
  
  
  RESULTS
  A total of 1,814 biopsy procedures were performed in 1,541 patients. For 1,246 patients, the procedure was the first biopsy, whereas for 295 patients it was a repeat biopsy. Twenty-one patients (1.36%) were identified as having acute bacterial prostatitis after the biopsy. Fifteen patients (1.2%) had acute prostatitis after the first biopsy, and 6 patients (2.03%) experienced acute prostatitis after a repeat biopsy. Even though the incidence of acute bacterial prostatitis was higher after repeat biopsy than that after the first biopsy, there was no statistically significant intergroup difference in terms of incidence (χ(2)=1.223, p=0.269). When the collected urine and blood samples were cultured, Escherichia coli was found in samples from 15 patients (71.4%), Klebsiella pneumoniae in 3 patients (14.3%), Enterobacter intermedius in 1 patient (4.8%), E. aerogenes in 1 patient (4.8%), and Pseudomonas aeruginosa in 1 patient (4.8%). A fluoroquinolone-resistant strain was confirmed in 5 cases (23.8%) in total. Three cases of E. coli and 1 case of Klebsiella had extended-spectrum β-lactamase activity.
  
  
  CONCLUSIONS
  Empirical treatment of acute prostatitis should be done with consideration of geographical prevalence and drug resistance. This study will provide meaningful information for the management of acute prostatitis after transrectal prostate biopsy.
authors.affiliation: Department of Urology, St. Vincent's Hospital, The Catholic University of Korea College of Medicine, Suwon, Korea.
authors.forename: Jun-Ho
authors.initials: JH
authors.lastname: Bang
authors.forename: Hyun-Sop
authors.initials: HS
authors.lastname: Choe
authors.forename: Dong-Sup
authors.initials: DS
authors.lastname: Lee
authors.forename: Seung-Ju
authors.initials: SJ
authors.lastname: Lee
authors.forename: Yong-Hyun
authors.initials: YH
authors.lastname: Cho
keywords: Acute diseases; Beta-lactamases; Biopsy; Fluoroquinolone; Prostate
references.citation: Antimicrob Agents Chemother. 2000 Aug;44(8):2046-51
references.pmid: 10898674
references.citation: Infect Control Hosp Epidemiol. 2004 Oct;25(10):873-7
references.pmid: 15518032
references.citation: Int J Antimicrob Agents. 2008 Feb;31 Suppl 1:S96-101
references.pmid: 18065208
references.citation: Urology. 1997 Jun;49(6):875-80
references.pmid: 9187694
references.citation: J Urol. 2001 Sep;166(3):856-60
references.pmid: 11490233
references.citation: J Urol. 2008 Mar;179(3):952-5; discussion 955
references.pmid: 18207185
references.citation: Hinyokika Kiyo. 2006 Aug;52(8):645-9
references.pmid: 16972630
references.citation: Korean J Urol. 2010 Jun;51(6):426-30
references.pmid: 20577611
references.citation: BJU Int. 2000 Apr;85(6):682-5
references.pmid: 10759665
references.citation: J Infect. 2007 Sep;55(3):254-9
references.pmid: 17574678
references.citation: Korean J Urol. 2011 Feb;52(2):119-23
references.pmid: 21379429
references.citation: Int J Urol. 2008 Oct;15(11):997-1001
references.pmid: 18721198
references.citation: Br J Urol. 1995 Sep;76(3):351-4
references.pmid: 7551845
references.citation: J Urol. 1979 Oct;122(4):492-4
references.pmid: 384025
references.citation: Actas Urol Esp. 2006 Oct;30(9):866-70
references.pmid: 17175926
references.citation: Urology. 2009 Jul;74(1):119-23
references.pmid: 19464043
references.citation: Urology. 1998 Oct;52(4):552-8
references.pmid: 9763070
references.citation: J Urol. 2000 Jul;164(1):76-80
references.pmid: 10840428
references.citation: J Urol. 2002 Sep;168(3):1021-3
references.pmid: 12187213
references.citation: Urology. 1991 Jul;38(1):84-7
references.pmid: 1866869
references.citation: World J Urol. 2005 Nov;23(5):356-60
references.pmid: 16254727
references.citation: Am J Infect Control. 2005 Aug;33(6):326-32
references.pmid: 16061138
references.citation: J Urol. 1982 Mar;127(3):449-51
references.pmid: 6895918
references.citation: Kansenshogaku Zasshi. 2002 Oct;76(10):893-7
references.pmid: 12448850
references.citation: Clin Infect Dis. 2001 Apr 15;32(8):1162-71
references.pmid: 11283805
references.citation: J Infect Chemother. 2008 Feb;14(1):40-3
references.pmid: 18297448
references.citation: J Antimicrob Chemother. 1997 Feb;39(2):115-7
references.pmid: 9069529
references.citation: Arch Intern Med. 2005 Jun 27;165(12):1375-80
references.pmid: 15983286
references.citation: J Urol. 2003 May;169(5):1762-5
references.pmid: 12686828
references.citation: J Hepatol. 1999 Aug;31(2):277-83
references.pmid: 10453941